Abstract
The intranasal respiratory syncytial virus (RSV) vaccine D46/cp/ΔM2-2 is attenuated by deletion of the RSV RNA synthesis factor M2-2 and 5 cold-passage amino acid mutations. D46/cp/ΔM2-2 was safe but overattenuated in 12- to 59-month-old RSV-seropositive children (dose: 106 plaque-forming units [PFU]) and 6- to 24-month-old RSV-seronegative children (dose: 105 PFU). Clinical Trials Registration. ClinicalTrials.gov Number . NCT02601612.
Funding Information
  • National Institutes of Health (75N93030F0001)
  • U.S. Department of Health and Human Services

This publication has 12 references indexed in Scilit: